逸達 (6576.TWO)

94.20 0.00 (0.00%) 收市：01:30PM CST

逸達

No. 19-3, Sanchong Road
9th Floor-2 Nangang District
Taipei 115
Taiwan
886 2 7750 0188
https://www.foreseepharma.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Benjamin Chien	Founder, CEO & Chairman	16.17M	無	無
Dr. Yuhua Li Ph.D.	Co-founder & Chief Technology Officer	3.06M	無	無
Dr. Mathieu Boudreau Ph.D.	Chief Business Officer & Chief Operating Officer	585k	無	無
Dr. Wenjin Yang Ph.D.	Chief Scientific Officer, Co-Acting Head of Clinical Development & VP	4.99M	無	無
Dr. Yisheng Lee Ph.D.	Chief Medical Officer, Acting Head of Clinical Development & Representative Director	1.99M	無	無
Dr. Jagdish Parasrampuria Ph.D.	Senior Vice President of Pharmaceutics and Manufacturing	5.46M	無	無
Mr. MengKung Chan	Chief Financial Officer	無	無	1967
Liang Chris	Accounting Officer	無	無	無
Dr. John Mao	Consultant	無	無	無
Ms. Peifen Chou	Consultant	無	無	1968

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.

公司管治

截至 無 止，逸達 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。